Davidj Kuter News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Study shows potential benefits of efgartigimod as a treatment for immune thrombocytopenia

Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential to clotting and stopping bleeding, compared to those taking a placebo, according to results reported from the ADVANCE IV clinical trial, which was conducted globally, including at Georgetown University Medical Center.

New yorkUnited statesFrance generalUnited kingdomCity ofYoshitaka miyakawaMarc michelFrancesco rodeghieroDavidj kuterAdrianc newlandMonica carpenedoEmily hendersonCatherine broomeVickie mcdonaldMarie godarJamesb bussel

Rigel Announces Five Poster Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition

/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the upcoming presentation of five posters highlighting data from the Company s.

United statesSouth san franciscoCecilf whitaker jrVadimv markovtsovDavid rosenMehdim moeziRaul rodriguezDavidj kuterJorgee cortesVickie mcdonaldHematology am soc hematol educ programConsultant haematologist at barts healthAmerican society of hematologyPrnewswire rigel pharmaceuticals incRigel pharmaceuticalsGeorgia cancer center

This drug for blood disorder shows promise in phase 1-2 clinical trial

This drug for blood disorder shows promise in phase 1-2 clinical trial
indianewengland.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indianewengland.com Daily Mail and Mail on Sunday newspapers.

New delhiUnited statesDavidj kuterNew england journalMassachusetts general hospital

This drug for blood disorder shows promise in phase 1-2 clinical trial

A drug called rilzabrutinib has generated promising safety and efficacy results in a recent international multi-centre phase 1-2 immune thrombocytopenia (ITP) trial, say researchers.In people with immune ITP, the body produces destructive .

New delhiUnited statesDavidj kuterNew england journalMassachusetts general hospital

Rilzabrutinib active, safe in immune thrombocytopenia

Rilzibrutinib induced rapid and durable clinical activity in previously treated patients with immune thrombocytopenia, according to results of a phase 1/phase 2 clinical trial published in The New England Journal of Medicine.Additionally, the oral Bruton tyrosine kinase inhibitor demonstrated a low-grade safety profile.

United statesSobi dovaTakeda bioverativDaiichi sankyoSanofi genzymeImmunovant incyteDavidj kuterRyan lawrenceSanofi principiaAlexion syntimmuneBristol myers squibbHarvard medical schoolPlatelet disorder support associationMerck sharpPlatelet biogenesisNew england journal